BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31685262)

  • 1. Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis.
    Fuentes HE; McBane RD; Wysokinski WE; Tafur AJ; Loprinzi CL; Murad MH; Riaz IB
    Mayo Clin Proc; 2019 Dec; 94(12):2444-2454. PubMed ID: 31685262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Riaz IB; Fuentes HE; Naqvi SAA; He H; Sipra QR; Tafur AJ; Padranos L; Wysokinski WE; Marshall AL; Vandvik PO; Montori V; Bryce AH; Liu H; Badgett RG; Murad MH; McBane RD
    Mayo Clin Proc; 2022 Feb; 97(2):308-324. PubMed ID: 34172290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
    Ay C; Beyer-Westendorf J; Pabinger I
    Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
    Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
    Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
    Brandão GMS; Malgor RD; Vieceli T; Cândido RCF; Inácio JFS; Rodrigues CG; Malgor EA; Sobreira ML
    Vascular; 2022 Feb; 30(1):130-145. PubMed ID: 33794711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
    Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
    PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.
    Mulder FI; Bosch FTM; Young AM; Marshall A; McBane RD; Zemla TJ; Carrier M; Kamphuisen PW; Bossuyt PMM; Büller HR; Weitz JI; Middeldorp S; van Es N
    Blood; 2020 Sep; 136(12):1433-1441. PubMed ID: 32396939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
    Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
    Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
    J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of nonmajor bleeding upon use of direct oral anticoagulants for preventing and treating venous thromboembolism: A network meta-analysis.
    Chen J; Lv M; Jiang S; Wu S; Xu W; Qian J; Zeng Z; Chen M; Fang Z; Zhang J
    Vasc Med; 2022 Dec; 27(6):565-573. PubMed ID: 36065470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.
    Elsebaie MAT; van Es N; Langston A; Büller HR; Gaddh M
    J Thromb Haemost; 2019 Apr; 17(4):645-656. PubMed ID: 30690830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
    Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
    [No Abstract]   [Full Text] [Related]  

  • 16. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
    Djulbegovic M; Lee AI; Chen K
    J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
    Chaudhary R; Pagali S; Garg J; Murad MH; Wysokinski WE; McBane RD
    J Am Geriatr Soc; 2020 Sep; 68(9):2021-2026. PubMed ID: 32441334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
    Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis.
    Ning H; Yang N; Ding Y; Chen H; Wang L; Han Y; Cheng G; Zou M
    Med Clin (Barc); 2023 Mar; 160(6):245-252. PubMed ID: 36031454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
    Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
    Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.